

Table of contents

1. General Methods	S2
2. Experiment procedure.....	S2
3. Spectral and Analytical Data of products.....	S3
4. NMR Spectrums for comounds 1-31 (Figure S1- S81)	S12

Formatted: Font: (Default) Times New Roman, (Asian) +Headings Asian (宋体)

Formatted: Font: (Default) Times New Roman

Field Code Changed

Formatted: Font: (Default) Times New Roman, 10.5 pt, N
Bold, Font color: Auto

Formatted: Font: (Default) Times New Roman, 10.5 pt, N
Bold, Font color: Auto

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, 10.5 pt, N
Bold, Font color: Auto

1. General Methods

Formatted: Font: (Asian) +Headings Asian (宋体)

All the chemicals were purchased from the commercial suppliers without further purification. All reactions were monitored by TLC, analytical thin-layer chromatography was performed on GF254 silica gel glass plates. Column chromatography was performed with silica gel (200-300 mesh). All unknown compounds were structurally verified by ^1H NMR, ^{13}C NMR and MS, and ^1H , ^{13}C NMR spectra were recorded on a Bruker Advance drx 400 spectrometer operating at 400MHz and 100 MHz, respectively, the chemical shifts are reported in ppm and the coupling constant in Hz. MS analysed for the known compounds by Waters HPLC/ZQ 4000.

2. Experiment procedure

Formatted: Font: (Asian) +Headings Asian (宋体)

2.1 General procedure for the synthesis of 2-phenylquinazolin-4(3H)-one(4aa):

Formatted: Font: (Asian) +Body Asian (宋体)

To a mixture of 2-Bromobenzonitrile (183.4 mg, 1 mmol), benzaldehyde (210.5 mg, 2 mmol), CuCl_2 (17.2 mg, 0.1 mmol), Cs_2CO_3 (652.2 mg, 2mmol), and L-proline (23.2 mg, 0.2 mmol) in H_2O (2 mL) was added 27% aqueous ammonia (1 mL) in a tube under air atmosphere. Then the tube was sealed, and the mixture was stirred at 100°C for 12 h. Next, the tube was opened to air and the mixture was stirred at 100°C for another 12 h. After being cooled to room temperature, the resulting mixture was quenched with NH_4Cl solution and extracted with ethyl acetate. The combined organic layer was washed with brine, and then dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica-gel to afford 2-phenylquinazolin-4(3H)-one (4aa) in 75% isolated yield. ^1H NMR (400 MHz, CDCl_3 -d) δ 11.24 (s, 1H, -NH-), 8.27 (d, $J = 7.8$ Hz, 1H, Ar-H), 8.16 (dd, $J = 6.6, 3.0$ Hz, 2H, Ar-H), 7.82 – 7.71 (m, 2H, Ar-H), 7.57 – 7.49 (m, 3H, Ar-H), 7.48 – 7.41 (m, 1H, Ar-H). ^{13}C NMR (101 MHz, CDCl_3 -d) δ 151.60, 134.87, 132.77, 131.64, 129.05, 127.97, 127.25, 126.79, 126.34, 120.84. HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{11}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 223.0866. Found: 223.0865.

Formatted: Font: (Default) 宋体, (Asian) 宋体, Not Bold

Formatted: Font: (Default) 宋体, (Asian) 宋体, Not Bold

Formatted: Font: Not Bold, Font color: Auto

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Not Bold, Font color: Auto

2.2 General procedure for the synthesis of 2-phenyl-2,3-dihydroquinazolin- 4(1H)-one(5aa):

2-bromobenzonitrile (182.3 mg, 1 mmol), benzaldehyde (213.6 mg, 2 mmol), CuCl_2 (17.1 mg, 0.1 mmol), Cs_2CO_3 (651.3 mg, 2 mmol) and L-proline 23.4 mg, 0.2 mmol) in H_2O (2 mL) were added into a tube and stirred. Remove the air inside the tube under the reduced pressure and flush with N_2 , repeat this operation 3 times and protected the starting materials under N_2 . 27% of Aqueous ammonia (1 mL) was added into the reaction mixture under nitrogen. The tube was then sealed and the mixture was stirred at 100°C for 24 hours. After cooling to room temperature, the resulting mixture was quenched with NH_4Cl solution and extracted with ethyl acetate. The combined organic layers were washed with brine and then dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica-gel to afford 2-phenyl-2,3-dihydroquinazolin-4(1H)-one(5aa) in 74% isolated yield. ^1H NMR (400 MHz, CDCl_3 -d) δ 7.97 (d, $J = 7.8$ Hz, 1H, Ar-H), 7.67 – 7.56 (m, 2H, Ar-H), 7.55 – 7.41 (m, 3H, Ar-H), 7.36 (t, $J = 7.7$ Hz, 1H, Ar-H), 6.93 (t, $J = 7.5$ Hz, 1H, Ar-H), 6.70 (d, $J = 8.0$ Hz, 1H, Ar-H), 5.93 (s, 1H, -CH-), 5.80 (s, 1H, -NH-), 4.42 (s, 1H, -NH-). ^{13}C NMR (101 MHz, DMSO) δ 163.98, 148.27, 142.04, 133.70, 128.85, 128.72, 127.75, 127.26, 117.51, 115.36, 114.80, 66.96. HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 225.1022. Found: 225.1021.

Commented [A1]:

2.3 General procedure for the synthesis of 2-phenylquinazolin-4(3H)-one (4aa) with Scheme 3:

p-aminobenzonitrile (119.8 mg, 1 mmol), benzaldehyde (217.8 mg, 2 mmol), CuCl₂ (17.6 mg, 0.1 mmol), Cs₂CO₃ (652.3 mg, 2 mmol) and L-proline 23.6 mg, 0.2 mmol) in H₂O (2 mL) was added in a 5 ml reaction bottle. The mixture was stirred at 100 °C for 48 hours. After cooling to room temperature, the resulting mixture was quenched with NH₄Cl solution and extracted with ethyl acetate. The combined organic layers were washed with brine and then dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica-gel to afford 2-phenylquinazolin-4(3H)-one (4aa) in 43% isolated yield.


2.4 General procedure for the synthesis of 2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5aa) with Scheme 3:

p-Aminobenzonitrile (120.8 mg, 1 mmol), benzaldehyde (216.7 mg, 2 mmol), CuCl₂ (17.3 mg, 0.1 mmol), Cs₂CO₃ (653.7 mg, 2 mmol) and L-proline (23.3 mg, 0.2 mmol) in H₂O (2 mL) was added in a 5 ml reaction bottle under nitrogen. Remove the air inside the tube under the reduced pressure and flush with N₂, repeat this operation 3 times and protected the starting materials under N₂. The mixture was stirred at 100 °C for 24 hours. After cooling to room temperature, the resulting mixture was quenched with NH₄Cl solution and extracted with ethyl acetate. The combined organic layers were washed with brine and then dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica-gel to afford 2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5aa) in 76% isolated yield.

2.5 General procedure for the synthesis of 2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5aa) with Scheme 4:

o-Aminobenzamide (139.1 mg, 1 mmol), benzaldehyde (209.9 mg, 2 mmol), CuCl₂ (17.6 mg, 0.1 mmol), Cs₂CO₃ (657.0 mg, 2 mmol) and L-proline (23.6 mg, 0.2 mmol) in H₂O (2 mL) was added in a 5 ml reaction bottle. The mixture was stirred at 100 °C for 14 hours. After cooling to room temperature, the resulting mixture was quenched with NH₄Cl solution and extracted with ethyl acetate. The combined organic layers were washed with brine and then dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica-gel to afford 2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5aa) in 95% isolated yield.


3. Spectral and Analytical Data of products



2-phenylquinazolin-4(3H)-one (4aa)[1]:

¹H NMR (400 MHz, CDCl₃-d) δ 11.24 (s, 1H, -NH-), 8.27 (d, *J* = 7.8 Hz, 1H, Ar-H), 8.16 (dd, *J* = 6.6, 3.0 Hz, 2H, Ar-H), 7.82 – 7.71 (m, 2H, Ar-H), 7.57 – 7.49 (m, 3H, Ar-H), 7.48 – 7.41 (m, 1H, Ar-H).

¹³C NMR (100 MHz, -CDCl₃-d) δ 151.60, 134.87, 132.77, 131.64, 129.05, 127.97, 127.25, 126.79, 126.34, 120.84. HRMS (ESI) calcd for C₁₄H₁₁N₂O [M+H]⁺: 223.0871. Found: 223.0866.




Formatted: Font: (Default) Times New Roman

2-(4-chlorophenyl)quinazolin-4(3H)-one (4ab)[1]:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.60 (s, 1H, $-\text{NH}-$), 8.21 (d, $J = 8.6$ Hz, 2H, Ar-H), 8.16 (d, $J = 7.8$ Hz, 1H, Ar-H), 7.85 (t, $J = 7.6$ Hz, 1H, Ar-H), 7.75 (d, $J = 8.1$ Hz, 1H, Ar-H), 7.63 (d, $J = 8.6$ Hz, 2H, Ar-H), 7.54 (t, $J = 7.4$ Hz, 1H, Ar-H).

^{13}C NMR (101 MHz, DMSO) δ 162.56, 151.74, 148.98, 136.70, 135.08, 131.97, 130.03, 129.10, 127.93, 127.19, 126.28, 121.42.




Formatted: Font: (Default) Times New Roman

2-(2-chlorophenyl)quinazolin-4(3H)-one (4ac)[1]:

^1H NMR (400 MHz, CDCl_3) δ 10.62 (s, 1H, $-\text{NH}-$), 8.27 (d, $J = 7.9$ Hz, 1H, Ar-H), 7.81 (d, $J = 4.0$ Hz, 3H, Ar-H), 7.58 – 7.40 (m, 4H, Ar-H).

^{13}C NMR (101 MHz, CDCl_3) δ 162.42, 151.12, 148.92, 134.83, 132.72, 132.03, 131.91, 131.34, 130.51, 127.91, 127.38, 127.30, 126.44, 121.02.




Formatted: Font: (Default) Times New Roman

2-(p-tolyl)quinazolin-4(3H)-one (4ad)[1]:

^1H NMR (400 MHz, CDCl_3) δ 11.28 (s, 1H, $-\text{NH}-$), 8.36 (d, $J = 7.9$ Hz, 1H, Ar-H), 8.15 (d, $J = 8.2$ Hz, 2H, Ar-H), 7.83 (q, $J = 8.4$ Hz, 2H, Ar-H), 7.52 (t, $J = 7.3$ Hz, 1H, Ar-H), 7.41 (d, $J = 8.0$ Hz, 2H, Ar-H), 2.49 (s, 3H, $-\text{CH}_3$).

^{13}C NMR (101 MHz, CDCl_3) δ 163.90, 151.80, 149.52, 142.15, 134.78, 129.87, 129.69, 127.81, 127.33, 126.50, 126.31, 120.72, 21.50.



Formatted: Font: (Default) Times New Roman


2-(4-methoxyphenyl)quinazolin-4(3H)-one (4ae)[1]:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.40 (s, 1H, $-\text{NH}-$), 8.17 (dd, $J = 25.4, 8.3$ Hz, 3H, Ar-H), 7.82 (t, $J = 7.5$ Hz, 1H, Ar-H), 7.71 (d, $J = 8.1$ Hz, 1H, Ar-H), 7.49 (t, $J = 7.5$ Hz, 1H, Ar-H), 7.09 (d, $J = 8.8$ Hz, 2H, Ar-H), 3.86 (s, 3H, $-\text{CH}_3$).

^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 162.70, 162.27, 152.26, 149.34, 134.94, 129.86, 127.69, 126.52, 126.23, 125.21, 121.10, 114.40, 55.86.

Formatted: Font: Italic

Formatted: Subscript




Formatted: Font: (Default) Times New Roman

2-(2-methoxyphenyl)quinazolin-4(3H)-one (4af)[1]:

^1H NMR (400 MHz, CDCl_3 -*d*) δ 10.92 (s, 1H, -NH-), 8.53 (d, J = 9.4 Hz, 1H, Ar-H), 8.30 (d, J = 7.8 Hz, 1H, Ar-H), 7.77 (q, J = 8.3 Hz, 2H, Ar-H), 7.55 – 7.43 (m, 2H, Ar-H), 7.16 (t, J = 7.6 Hz, 1H, Ar-H), 7.06 (d, J = 8.4 Hz, 1H, Ar-H), 4.05 (s, 3H, -CH₃).

^{13}C NMR (101 MHz, CDCl_3) δ 161.82, 157.72, 150.71, 149.32, 134.40, 133.13, 131.47, 127.78, 126.39, 126.34, 121.79, 121.12, 119.84, 111.77, 56.09.




Formatted: Font: (Default) Times New Roman

2-(4-hydroxyphenyl)quinazolin-4(3H)-one (4ag)[2]:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.30 (s, 1H, -NH-), 10.15 (s, 1H, -OH), 8.11 (dd, J = 12.1, 8.6 Hz, 3H, Ar-H), 7.80 (t, J = 7.5 Hz, 1H, Ar-H), 7.68 (d, J = 8.1 Hz, 1H, Ar-H), 7.47 (t, J = 7.4 Hz, 1H, Ar-H), 6.90 (d, J = 8.5 Hz, 2H, Ar-H).

^{13}C NMR (101 MHz, DMSO) δ 162.71, 160.96, 152.53, 149.45, 134.88, 129.98, 127.60, 126.31, 126.22, 123.62, 120.99, 115.76.




Formatted: Font: (Default) Times New Roman

2-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (4ai)[3]:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.74 (s, 1H, -NH-), 8.38 (d, J = 8.1 Hz, 2H, Ar-H), 8.19 (d, J = 7.9 Hz, 1H, Ar-H), 7.93 (d, J = 8.2 Hz, 2H, Ar-H), 7.87 (t, J = 7.6 Hz, 1H, Ar-H), 7.78 (d, J = 8.1 Hz, 1H, Ar-H), 7.57 (t, J = 7.5 Hz, 1H, Ar-H).

^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 162.52, 151.58, 148.84, 137.02, 135.14, 131.51 (d, $^1J_{C,F}$ = 31.7 Hz), 129.14, 128.09, 127.52, 126.31, 125.90 (dd, $^3J_{C,F}$ = 3.7, $^2J_{C,F}$ = 13.1 Hz), 123.01, 121.61.

^{19}F NMR (376 MHz, DMSO) δ -61.35.




Formatted: Font: (Default) Times New Roman

2-(4-(dimethylamino)phenyl)quinazolin-4(3H)-one (4aj)[4]:

^1H NMR (400 MHz, CDCl_3 -*d*) δ 10.70 (s, 1H, -NH-), 8.32 (d, J = 7.7 Hz, 1H, Ar-H), 8.11 (d, J = 9.0 Hz, 2H, Ar-H), 7.78 (s, 2H, Ar-H), 7.44 (s, 1H, Ar-H), 6.82 (d, J = 9.0 Hz, 2H, Ar-H), 3.10 (s, 6H, -CH₃).

^{13}C NMR (101 MHz, CDCl_3) δ 163.47, 152.54, 151.79, 149.82, 134.62, 128.45, 127.31, 126.31, 125.63,


120.30, 119.00, 111.64, 40.08.



2-(naphthalen-2-yl)quinazolin-4(3H)-one (4ak)[2]:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.67 (s, 1H, -NH-), 8.83 (s, 1H, Ar-H), 8.36 – 8.26 (m, 1H, Ar-H), 8.24 – 8.16 (m, 1H, Ar-H), 8.05 (d, J = 16.5 Hz, 3H, Ar-H), 7.84 (d, J = 21.9 Hz, 2H, Ar-H), 7.60 (d, J = 38.2 Hz, 3H, Ar-H).


^{13}C NMR (101 MHz, DMSO) δ 162.65, 152.64, 149.19, 135.07, 134.54, 132.69, 130.37, 129.37, 128.58, 128.52, 128.34, 128.08, 127.97, 127.33, 127.08, 126.32, 124.91, 121.46.



2-(pyridin-4-yl)quinazolin-4(3H)-one (4al)[3]:

^1H NMR (400 MHz, $-\text{CDCl}_3-d$) δ 12.03 (s, 1H, -NH-), 8.93 (d, J = 5.5 Hz, 2H, Ar-H), 8.40 (d, J = 7.9 Hz, 1H, Ar-H), 8.23 (d, J = 5.8 Hz, 2H, Ar-H), 7.90 (d, J = 6.1 Hz, 2H, Ar-H), 7.63 (ddd, J = 8.1, 6.0, 2.2 Hz, 1H, Ar-H).


^{13}C NMR (101 MHz, DMSO) δ 162.43, 150.94, 150.69, 148.68, 140.33, 135.19, 128.21, 127.81, 126.34, 121.99, 121.90.



2-(1H-pyrrol-2-yl)quinazolin-4(3H)-one (4ap)[5]:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.20 (s, 1H, -NH-), 11.74 (s, 1H, -NH-), 8.09 (d, J = 7.7 Hz, 1H, Ar-H), 7.77 (t, J = 7.4 Hz, 1H, Ar-H), 7.62 (d, J = 8.1 Hz, 1H, Ar-H), 7.41 (t, J = 7.4 Hz, 1H, Ar-H), 7.31 (s, 1H, Ar-H), 7.04 (s, 1H, Ar-H), 6.22 (s, 1H, Ar-H).

^{13}C NMR (101 MHz, DMSO) δ 162.30, 149.71, 146.80, 134.91, 126.85, 126.37, 125.62, 124.69, 124.27, 120.90, 112.89, 110.15.



6-fluoro-2-phenylquinazolin-4(3H)-one (4ea)[6]:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.66 (s, 1H, -NH-), 8.18 (d, J = 6.9 Hz, 2H, Ar-H), 7.87 – 7.80 (m, 2H, Ar-H), 7.73 (td, J = 8.7, 3.0 Hz, 1H, Ar-H), 7.63 – 7.52 (m, 3H, Ar-H).

^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 162.06, 160.40 (d, $^1J_{\text{C},\text{F}}$ = 246.5 Hz), 152.27, 146.04, 132.97, 131.83, 130.74 (d, $^3J_{\text{C},\text{F}}$ = 8.4 Hz), 129.02, 128.16, 123.47 (d, $^2J_{\text{C},\text{F}}$ = 24.3 Hz), 122.61 (d, $^3J_{\text{C},\text{F}}$ = 9.5

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman


Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman

Commented [微软中国2]: 注意首字母大写的问题


Formatted: Font color: Text 1

Hz), 110.92 (d, $^2J_{C,F}$ = 23.2 Hz). ^{19}F NMR (376 MHz, DMSO) δ -113.49, -113.50, -113.51, -113.53, -113.53, -113.55.




6-fluoro-2-(4-methoxyphenyl)quinazolin-4(3H)-one (4ee)^[7]:

^1H NMR (400 MHz, CDCl_3 -d) δ 9.87 (s, 1H, -NH-), 8.05 (d, J = 8.3 Hz, 2H, Ar-H), 7.95 (d, J = 7.5 Hz, 1H, Ar-H), 7.82 (dd, J = 8.9, 4.6 Hz, 1H, Ar-H), 7.54 (d, J = 6.8 Hz, 1H, Ar-H), 7.13 – 7.06 (m, 2H, Ar-H), 3.94 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, DMSO- d_6) δ 162.30, 162.13 (d, $^4J_{C,F}$ = 3.0 Hz), 160.14 (d, $^1J_{C,F}$ = 245.0 Hz), 151.84, 146.25, 130.48 (d, $^3J_{C,F}$ = 8.2 Hz), 129.85, 125.05, 123.42 (d, $^2J_{C,F}$ = 24.1 Hz), 122.24 (d, $^3J_{C,F}$ = 8.4 Hz), 114.43, 110.85 (d, $^2J_{C,F}$ = 23.2 Hz), 55.88. ^{19}F NMR (376 MHz, DMSO) δ -114.17. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FN}_2\text{O}_2$ [M+H]⁺: 271.0877. Found: 271.0876.




6-fluoro-2-(2-methoxyphenyl)quinazolin-4(3H)-one (4ef)^[7]:

^1H NMR (400 MHz, CDCl_3 -d) δ 11.00 (s, 1H, -NH-), 8.53 (d, J = 7.9 Hz, 1H, Ar-H), 7.94 (d, J = 8.3 Hz, 1H, Ar-H), 7.80 (dd, J = 8.9, 4.9 Hz, 1H, Ar-H), 7.57 – 7.46 (m, 2H, Ar-H), 7.18 (t, J = 7.6 Hz, 1H, Ar-H), 7.09 (d, J = 8.4 Hz, 1H, Ar-H), 4.08 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, DMSO- d_6) δ 161.07 (d, $^4J_{C,F}$ = 3.4 Hz), 160.40 (d, $^1J_{C,F}$ = 245.43 Hz), 157.52, 152.27, 146.33, 132.66, 130.85, 130.65 (d, $^3J_{C,F}$ = 8.5 Hz), 123.32 (d, $^2J_{C,F}$ = 23.9 Hz), 122.95, 122.62 (d, $^3J_{C,F}$ = 8.5 Hz), 120.82, 112.26, 10.83 (d, $^2J_{C,F}$ = 23.4 Hz), 56.17. ^{19}F NMR (376 MHz, DMSO) δ -113.56.



6-fluoro-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one (4eq):

^1H NMR (400 MHz, DMSO- d_6) δ 12.47 (s, 1H, -NH-), 9.76 (s, 1H, -OH), 8.09 – 7.61 (m, 5H, Ar-H), 6.91 (d, J = 8.3 Hz, 1H, Ar-H), 3.90 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, DMSO- d_6) δ 162.23, 160.02 (d, $^1J_{C,F}$ = 244.7 Hz), 152.02, 150.38, 147.89, 146.33, 130.38, 123.62, 123.38 (d, $^2J_{C,F}$ = 24.2 Hz), 122.07 (d, $^3J_{C,F}$ = 7.9 Hz), 121.87, 115.83, 111.73, 110.83 (d, $^2J_{C,F}$ = 23.2 Hz), 56.19. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FN}_2\text{O}_3$ [M+H]⁺: 287.0826. Found: 287.0825. ^{19}F NMR (376 MHz, DMSO) δ -114.53.



6-methyl-2-phenylquinazolin-4(3H)-one (4fa)^[3]:

^1H NMR (400 MHz, CDCl_3 -d) δ 10.82 (s, 1H, -NH-), 8.19 (d, J = 5.7 Hz, 2H, Ar-H), 8.14 (s, 1H, Ar-

Formatted: Font: (Default) +Body (Calibri), 10.5 pt

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman


Formatted: Font: (Default) Times New Roman

Commented [微软中国3]: 注意斜体

Formatted: Font: Italic


Formatted: Font: (Default) Times New Roman

H), 7.76 (d, $J = 8.3$ Hz, 1H, Ar-H), 7.64 (d, $J = 19.1$ Hz, 4H, Ar-H), 2.55 (s, 3H, -CH₃). ¹³C NMR (101 MHz, DMSO) δ 162.56, 151.86, 147.15, 136.71, 136.28, 133.19, 131.63, 128.99, 128.04, 127.79, 125.65, 121.13, 21.26.




2-(4-chlorophenyl)-6-methylquinazolin-4(3H)-one (4fb)[8]:

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.53 (s, 1H, -NH-), 8.20 (d, $J = 8.3$ Hz, 2H, Ar-H), 7.96 (s, 1H, Ar-H), 7.63 (s, 4H, Ar-H), 2.47 (s, 3H, -CH₃). ¹³C NMR (101 MHz, DMSO) δ 162.49, 150.95, 147.00, 136.95, 136.53, 136.35, 132.05, 129.91, 129.08, 127.82, 125.68, 121.16, 21.27.




2-(4-methoxyphenyl)-6-methylquinazolin-4(3H)-one (4fe)[3]:

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.32 (s, 1H, -NH-), 8.18 (d, $J = 8.8$ Hz, 2H, Ar-H), 7.93 (s, 1H, Ar-H), 7.67 – 7.58 (m, 2H, Ar-H), 7.08 (d, $J = 8.8$ Hz, 2H, Ar-H), 3.85 (s, 3H, -CH₃), 2.45 (s, 3H, -CH₃). ¹³C NMR (101 MHz, DMSO) δ 162.68, 162.14, 151.47, 147.34, 136.20, 136.16, 129.70, 127.54, 125.62, 125.31, 120.82, 114.37, 55.84, 21.22.



2-(2-methoxyphenyl)-6-methylquinazolin-4(3H)-one (4ff):

¹H NMR (400 MHz, CDCl₃-*d*) δ 10.88 (s, 1H, -NH-), 8.52 (d, $J = 7.6$ Hz, 1H, Ar-H), 8.10 (s, 1H, Ar-H), 7.69 (d, $J = 8.3$ Hz, 1H, Ar-H), 7.58 (d, $J = 9.8$ Hz, 1H, Ar-H), 7.50 (t, $J = 7.8$ Hz, 1H, Ar-H), 7.16 (t, $J = 7.6$ Hz, 1H, Ar-H), 7.06 (d, $J = 8.4$ Hz, 1H, Ar-H), 4.05 (s, 3H, -CH₃), 2.50 (s, 3H, -CH₃). ¹³C NMR (101 MHz, DMSO) δ 161.54, 157.55, 151.88, 147.46, 144.31, 136.62, 136.09, 132.52, 130.83, 127.68, 125.54, 123.08, 120.85, 112.29, 56.19, 21.25. HRMS (ESI) calcd for C₁₆H₁₅N₂O₂[M+H]⁺: 267.1128. Found: 267.1127.



6-methoxy-2-(4-methoxyphenyl)quinazolin-4(3H)-one (4ge)[9]:


¹H NMR (400 MHz, DMSO-*d*₆) δ 12.37 (s, 1H, -NH-), 8.17 (d, $J = 8.8$ Hz, 2H, Ar-H), 7.66 (d, $J = 8.9$ Hz, 1H, Ar-H), 7.53 (d, $J = 2.8$ Hz, 1H, Ar-H), 7.42 (d, $J = 11.8$ Hz, 1H, Ar-H), 7.08 (d, $J = 8.8$ Hz, 2H, Ar-H), 3.89 (s, 3H, -CH₃), 3.85 (s, 3H, -CH₃). ¹³C NMR (101 MHz, DMSO) δ 162.51, 161.98, 157.83,

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman


150.14, 143.82, 129.53, 129.41, 125.35, 124.51, 121.84, 114.38, 106.22, 56.02, 55.84.



Formatted: Font: (Default) Times New Roman

2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5aa)[10]:


^1H NMR (400 MHz, CDCl_3 -*d*) δ 7.97 (d, J = 7.8 Hz, 1H, Ar-H), 7.67 – 7.56 (m, 2H, Ar-H), 7.55 – 7.41 (m, 3H, , Ar-H), 7.36 (t, J = 7.7 Hz, 1H, Ar-H), 6.93 (t, J = 7.5 Hz, 1H, Ar-H), 6.70 (d, J = 8.0 Hz, 1H, Ar-H), 5.93 (s, 1H, -CH-), 5.80 (s, 1H, -NH-), 4.42 (s, 1H, -NH-). ^{13}C NMR (101 MHz, DMSO) δ 163.98, 148.27, 142.04, 133.70, 128.85, 128.72, 127.75, 127.26, 117.51, 115.36, 114.80, 66.96. HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}[\text{M}+\text{H}]^+$: 225.1022. Found: 225.1021.



Formatted: Font: (Default) Times New Roman

2-(4-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (5ab)[11]:


^1H NMR (400 MHz, DMSO-*d*₆) δ 8.33 (s, 1H, -NH-), 7.62 (dd, J = 7.7, 1.5 Hz, 1H, Ar-H), 7.52 (d, J = 8.6 Hz, 2H, Ar-H), 7.49 – 7.43 (m, 2H, Ar-H), 7.30 – 7.21 (m, 1H, Ar-H), 7.14 (s, 1H, -CH-), 6.75 (d, J = 7.7 Hz, 1H, Ar-H), 6.69 (t, J = 7.9 Hz, 1H, Ar-H), 5.78 (s, 1H, -NH-). ^{13}C NMR (101 MHz, DMSO) δ 163.90, 148.06, 141.08, 133.80, 133.39, 129.16, 128.72, 127.78, 117.70, 115.36, 114.87, 66.18.



Formatted: Font: (Default) Times New Roman

2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one (5ae)[10]:

^1H NMR (400 MHz, DMSO-*d*₆) δ 8.18 (s, 1H, -NH-), 7.62 (d, J = 9.1 Hz, 1H, Ar-H), 7.42 (d, J = 8.7 Hz, 2H, Ar-H), 7.28 – 7.20 (m, 1H, Ar-H), 7.01 (s, 1H, -NH-), 6.95 (d, J = 8.7 Hz, 2H, Ar-H), 6.75 (d, J = 7.8 Hz, 1H, Ar-H), 6.68 (t, J = 7.9 Hz, 1H, Ar-H), 5.71 (s, 1H, -CH-), 3.75 (s, 3H -CH₃). ^{13}C NMR (101 MHz, DMSO) δ 164.10, 159.84, 148.42, 133.88, 133.64, 128.62, 127.75, 117.49, 115.41, 114.82, 114.04, 66.72, 55.58.




Formatted: Font: (Default) Times New Roman

2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one (5af)¹³⁷:

^1H NMR (400 MHz, CDCl_3 -*d*) δ 7.91 (d, J = 7.8 Hz, 1H, Ar-H), 7.56 (d, J = 7.6 Hz, 1H, Ar-H), 7.32 (dt, J = 15.4, 7.6 Hz, 2H, Ar-H), 7.02 – 6.91 (m, 2H, Ar-H), 6.84 (t, J = 7.5 Hz, 1H, Ar-H), 6.67 (d, J = 8.1 Hz, 1H, Ar-H), 6.28 (s, 1H, -CH-), 6.25 (s, 1H, -NH-), 4.76 (s, 1H, -NH-), 3.90 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, CDCl_3) δ 164.99, 156.35, 147.07, 133.87, 130.11, 128.46, 127.84, 126.66, 120.90, 119.01, 115.21, 114.57, 110.58, 62.43, 55.43.


Formatted: Superscript

Formatted: Superscript




6-fluoro-2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5ea):

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.48 (s, 1H, -NH-), 7.52 (dd, J = 8.0, 1.3 Hz, 2H, Ar-H), 7.46 – 7.32 (m, 4H, Ar-H), 7.16 (td, J = 8.7, 3.1 Hz, 1H, Ar-H), 7.10 (s, 1H, -NH-), 6.81 (dd, J = 8.9, 4.5 Hz, 1H, Ar-H), 5.77 (s, 1H, -CH-). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 163.22, 155.14 (d, $^1J_{\text{C},\text{F}}$ = 233.4 Hz), 145.04, 141.57, 128.97, 128.75, 127.37, 121.17 (d, $^2J_{\text{C},\text{F}}$ = 23.4 Hz), 116.58 (d, $^3J_{\text{C},\text{F}}$ = 7.1 Hz), 116.12 (d, $^3J_{\text{C},\text{F}}$ = 6.6 Hz), 112.90 (d, $^2J_{\text{C},\text{F}}$ = 22.9 Hz), 67.14. ^{19}F NMR (376 MHz, DMSO) δ -125.22.




2-(4-chlorophenyl)-6-fluoro-2,3-dihydroquinazolin-4(1H)-one (5eb):

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.50 (s, 1H, -NH-), 7.55 – 7.49 (m, 2H, Ar-H), 7.49 – 7.43 (m, 2H, Ar-H), 7.32 (dd, J = 9.0, 3.1 Hz, 1H, Ar-H), 7.16 (td, J = 8.7, 3.1 Hz, 1H, Ar-H), 7.12 (s, 1H, -NH-), 6.79 (dd, J = 8.9, 4.5 Hz, 1H), 5.77 (s, 1H, -CH-). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 163.07, 155.20 (d, $^1J_{\text{C},\text{F}}$ = 233.5 Hz), 144.79, 140.62, 133.50, 129.24, 128.74, 121.26 (d, $^2J_{\text{C},\text{F}}$ = 23.5 Hz), 116.67 (d, $^3J_{\text{C},\text{F}}$ = 7.1 Hz), 116.12 (d, $^3J_{\text{C},\text{F}}$ = 6.9 Hz), 112.92 (d, $^2J_{\text{C},\text{F}}$ = 22.9 Hz), 66.31. ^{19}F NMR (376 MHz, DMSO) δ -125.77.




6-fluoro-2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one (5ec):

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.36 (s, 1H, -NH-), 7.42 (d, J = 8.6 Hz, 2H, Ar-H), 7.32 (dd, J = 9.0, 3.0 Hz, 1H, Ar-H), 7.15 (td, J = 8.7, 3.1 Hz, 1H, Ar-H), 6.99 (s, 1H, Ar-H), 6.97 (s, 1H, Ar-H), 6.95 (s, 1H, -CH-), 6.78 (dd, J = 8.9, 4.5 Hz, 1H, Ar-H), 5.70 (s, 1H, -NH-), 3.76 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 163.31, 159.93, 155.14 (d, $^1J_{\text{C},\text{F}}$ = 233.3 Hz), 145.18, 133.39, 128.71, 121.08 (d, $^2J_{\text{C},\text{F}}$ = 23.4 Hz), 116.57 (d, $^3J_{\text{C},\text{F}}$ = 7.1 Hz), 116.17 (d, $^3J_{\text{C},\text{F}}$ = 6.8 Hz), 114.06, 112.88 (d, $^2J_{\text{C},\text{F}}$ = 23.1 Hz), 66.89, 55.57. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{14}\text{FN}_2\text{O}_2[\text{M}+\text{H}]^+$: 273.1034 Found: 273.1032. ^{19}F NMR (376 MHz, DMSO) δ -125.76.




6-fluoro-2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one (5eq):

^1H NMR (400 MHz, DMSO- d_6) δ 8.19 (s, 1H, -NH-), 7.42 (d, J = 7.5 Hz, 1H, Ar-H), 7.38 – 7.30 (m, 2H, Ar-H), 7.18 – 7.09 (m, 1H, Ar-H), 7.06 (d, J = 8.2 Hz, 1H, Ar-H), 6.96 (t, J = 7.5 Hz, 1H, Ar-H), 6.81 (dd, J = 8.9, 4.5 Hz, 1H, Ar-H), 6.78 (s, 1H, -NH-), 6.03 (s, 1H, -CH-), 3.84 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, DMSO- d_6) δ 163.44, 156.82, 155.09 (d, $^1J_{\text{C},\text{F}}$ = 233.3 Hz), 145.14, 130.14, 128.93, 127.37, 121.08 (d, $^2J_{\text{C},\text{F}}$ = 23.3 Hz), 120.55, 116.65 (d, $^3J_{\text{C},\text{F}}$ = 7.1 Hz), 115.85 (d, $^3J_{\text{C},\text{F}}$ = 6.7 Hz), 112.84 (d, $^2J_{\text{C},\text{F}}$ = 22.9 Hz), 111.51, 61.54, 55.93. HRMS (ESI) calcd for C₁₅H₁₄N₂O₂[M+H]⁺: 273.1034. Found: 273.1032. ^{19}F NMR (376 MHz, DMSO) δ -126.07.




6-methyl-2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5fa)

^1H NMR (400 MHz, CDCl₃- d) δ 7.77 (s, 1H, Ar-H), 7.60 (dd, J = 6.5, 2.7 Hz, 2H), Ar-H, 7.49 – 7.42 (m, 3H, Ar-H), 7.16 (d, J = 9.3 Hz, 1H, Ar-H), 6.63 – 6.56 (m, 1H, Ar-H), 5.86 (s, 1H, -CH-), 5.73 (s, 1H, -NH-), 4.26 (s, 1H, -NH-), 2.30 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, DMSO) δ 163.43, 156.53, 153.92, 145.12, 130.13, 128.94, 127.36, 121.07, 120.55, 116.64, 115.84, 112.82, 111.53, 61.53, 55.95.



2-(4-chlorophenyl)-6-methyl-2,3-dihydroquinazolin-4(1H)-one (5fb)

^1H NMR (400 MHz, DMSO- d_6) δ 8.28 (s, 1H, Ar-H), 7.55 – 7.40 (m, 5H, Ar-H), 7.08 (d, J = 8.2 Hz, 1H, Ar-H), 6.95 (s, 1H, -CH-), 6.67 (d, J = 8.2 Hz, 1H, -NH-), 5.72 (s, 1H, -NH-), 2.18 (s, 3H, -CH₃).



2-(4-methoxyphenyl)-6-methyl-2,3-dihydroquinazolin-4(1H)-one (5fe)

^1H NMR (400 MHz, DMSO- d_6) δ 8.11 (s, 1H, Ar-H), 7.46 – 7.31 (m, 3H, Ar-H), 7.06 (dd, J = 8.2, 1.9 Hz, 1H, Ar-H), 6.93 (d, J = 8.7 Hz, 2H, Ar-H), 6.80 (s, 1H, -CH-), 6.66 (d, J = 8.2 Hz, 1H, -NH-), 5.65 (s, 1H, -NH-), 3.74 (s, 3H, -CH₃), 2.18 (s, 3H, -CH₃). ^{13}C NMR (101 MHz, DMSO) δ 164.23, 159.80, 146.28, 134.45, 133.92, 128.63, 127.60, 126.15, 115.47, 114.97, 114.00, 66.84, 55.57, 20.50. HRMS (ESI) calcd for C₁₆H₁₇N₂O₂[M+H]⁺: 269.1285. Found: 269.1283.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Font: (Default) Times New Roman

Formatted: Font: Not Bold, Superscript

Field Code Changed

Formatted: Font color: Red

4. NMR Spectrums for comounds 1-32 (Figure S1- S33S72)




Figure S1

Fig. S1. ¹H NMR for compound 1 (4aa) 2-phenylquinazolin-4(3H)-one.




Figure S2

Fig. S2. ^{13}C NMR for compound 1 (4aa) 2-phenylquinazolin-4(3H)-one.




Figure S3HRMS for compound 1 (4aa) 2-phenylquinazolin-4(3H)-one.




Figure S4

Fig. S3. ^1H NMR for compound 2 (4ab) 2-(4-chlorophenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S5

Fig-S3. ¹³C NMR for compound 2 (4ab)2-(4-chlorophenyl)quinazolin-4(3H)-one.




Figure S6

Fig-S4. ¹H NMR for compound 3 (4ac)2-(2-chlorophenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S7 ¹³C NMR for compound 3 (4ac) 2-(2-chlorophenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S8

Fig.-S5: ¹H NMR for compound 4 (4ad) 2-(*p*-tolyl)quinazolin-4(3H)-one.

Formatted: Font: 10 pt, Not Bold

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S9 ¹³C NMR for compound 4 (4ad) 2-(p-tolyl)quinazolin-4(3H)-one.




Figure S10

Fig. S6. ¹H NMR for compound 5 (4ae) 2-(4-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Font: Not Bold

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S11 ¹³C NMR for compound 5 (4ae) 2-(4-methoxyphenyl)quinazolin-4(3H)-one.




Figure S12

Fig-S7. ¹H NMR for compound 6 (4af) 2-(2-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman, 10 pt, No Bold

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S13 ¹³C NMR for compound 6 (4af) 2-(2-methoxyphenyl)quinazolin-4(3H)-one.




Figure S14

Fig. S8. ¹H NMR for compound 7 (4ag) 2-(4-hydroxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: 10 pt, Not Bold

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S15

Fig. S8. ¹³C NMR for compound 7 (4a) 2-(4-hydroxyphenyl)quinazolin-4(3H)-one.




Figure S16

Fig. S9. ¹H NMR for compound 8 (4ai) 2-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S17 ¹³C NMR for compound 8 (4ai) 2-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one.




Figure S18 ¹⁹F NMR for compound 8 (4ai) 2-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Font: (Default) +Body (Calibri), 10.5 pt, Not




Figure S19

Fig. S10. ¹H NMR for compound 9 (4aj) 2-(4-(dimethylamino)phenyl)quinazolin-4(3H)-one.




Figure S20 ¹³C NMR for compound 9 (4aj) 2-(4-(dimethylamino)phenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Font: (Default) Times New Roman, 12 pt, No Bold




Figure S21

Fig. S11 ¹H NMR for compound 10 (4a) 2-(naphthalen-2-yl)quinazolin-4(3H)-one.




Figure S22 ¹³C NMR for compound 10 (4a) 2-(naphthalen-2-yl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S23

Fig. S12. ¹H NMR for compound 11 (4a) 2-(pyridin-4-yl)quinazolin-4(3H)-one.




Figure S24 Fig. S12. ¹³C NMR for compound 11 (4a) 2-(pyridin-4-yl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S25

Fig-S13. ¹H NMR for compound 12 (4ap) 2-(1H-pyrrol-2-yl)quinazolin-4(3H)-one.






Figure S26 ¹³C NMR for compound 12 (4ap) 2-(1H-pyrrol-2-yl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold



Formatted: Font: (Default) Times New Roman



Formatted: Font: (Default) Times New Roman, Not Bold

Figure S28 **Fig-S14:** ^{13}C NMR for compound 13 (4ea) 6-fluoro-2-phenylquinazolin-4(3H)-one.




Figure S29 ^{19}F NMR for compound 13 (4ea) 6-fluoro-2-phenylquinazolin-4(3H)-one.




Figure S30

Fig. S15: ^1H NMR for compound 14 (4ec) 6-fluoro-2-(4-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S 31 ¹³C NMR for compound 14 (4ee) 6-fluoro-2-(4-methoxyphenyl)quinazolin-4(3H)-one.




Figure S 32 ¹⁹F NMR for compound 14 (4ee) 6-fluoro-2-(4-methoxyphenyl)quinazolin-4(3H)-one.




Figure S33HRMS for compound 14 (4ee) 6-fluoro-2-(4-methoxyphenyl)quinazolin-4(3H)-one.




Figure S34

Fig. S16-¹H NMR for compound 15 (4ef)6-fluoro-2-(2-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S35 ¹³C NMR for compound 15 (4ef) 6-fluoro-2-(2-methoxyphenyl)quinazolin-4(3H)-one.




Figure S 36 ¹⁹F NMR for compound 15 (4ef) 6-fluoro-2-(2-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S37

Fig.S17.1 ¹H NMR for compound 16 (4eq) 6-fluoro-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Superscript

Formatted: Font: Not Bold, Superscript




Figure S38 Fig.S17.1 ¹³C NMR for compound 16 (4eq) 6-fluoro-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: Not Bold, Superscript




Figure S3 ^{19}F NMR for compound 16 (4eq) 6-fluoro-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Asian) 黑体, 10 pt, Not Bold, Superscript

4eq(*) #4-41 RT: 0.02-0.22 AV: 38 NL: 8.53E6
T: FTMS + p ESI Full ms [150.0000-1000.0000]




Figure S4 HRMS for compound 16 (4eq) 6-fluoro-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one.




Figure S41

Fig.S41: ¹H NMR for compound 17 (4fa) 6-methyl-2-phenylquinazolin-4(3H)-one.




Figure S42 ¹³C NMR for compound 17 (4fa) 6-methyl-2-phenylquinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Font: (Default) Times New Roman, Not Bold




Fig. S19. ¹H NMR for compound 18 (4f) 2-(4-chlorophenyl)-6-methylquinazolin-4(3H)-one.




Figure S44 Fig. S19. ¹³C NMR for compound 18 (4fb) 2-(4-chlorophenyl)-6-methylquinazolin-4(3H)-one.




Figure S45

Fig. S20. ¹H NMR for compound 19 (4fe) 2-(4-methoxyphenyl)-6-methylquinazolin-4(3H)-one.




Figure S46 Fig. S20. ¹³C NMR for compound 19 (4fe) 2-(4-methoxyphenyl)-6-methylquinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Fig. S21. ¹H NMR for compound 20 (4ff) 2-(2-methoxyphenyl)-6-methylquinazolin-4(3H)-one.




Figure S48 Fig. S21. ¹³C NMR for compound 20 (4f) 2-(2-methoxyphenyl)-6-methylquinazolin-4(3H)-one.




Figure S49 HRMS for compound 20 (4ff) 2-(2-methoxyphenyl)-6-methylquinazolin-4(3H)-one.




Figure S50

Fig. S22. ¹H NMR for compound 21 (4ge) 6-methoxy-2-(4-methoxyphenyl)quinazolin-4(3H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S51 ^{13}C NMR for compound 21 (4ge) 6-methoxy-2-(4-methoxyphenyl)quinazolin-4(3H)-one.




Figure S52

Fig-S23. ^1H NMR for compound 22 (5aa) 2-phenyl-2,3-dihydroquinazolin-4(1H)-one.

Formatted: Font: (Default) Times New Roman, Not Bold

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S53 ¹³C NMR for compound 22 (5aa) 2-phenyl-2,3-dihydroquinazolin-4(1H)-one.




Figure S54 HRMS for compound 22 (5aa) 2-phenyl-2,3-dihydroquinazolin-4(1H)-one.




Figure S55

Fig. S24. ¹H NMR for compound 23 (5ab) 2-(4-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S56 Fig. S24. ¹³C NMR for compound 23 (5ab) 2-(4-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S57

Fig. S25: ¹H NMR for compound 24 (5ac) 2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S58 Fig. S25: ¹³C NMR for compound 24 (5ac) 2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold





Fig. S26: ¹H NMR for compound 25 (5af)2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S61 Fig. S26. ¹³C NMR for compound 25 (5af) 2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S62
Fig. S27: ¹H NMR for compound 26 (5ea) 6-fluoro-2-phenyl-2,3-dihydroquinazolin-4(1H)-one.




Figure S63 Fig. S27. ¹³C NMR for compound 26 (5ea) 6-fluoro-2-phenyl-2,3-dihydroquinazolin-4(1H)-one.




Figure S 64 ¹⁹F NMR for compound 26 (5ea) 6-fluoro-2-phenyl-2,3-dihydroquinazolin-4(1H)-one.




Figure S65

Fig. S28: ¹H NMR for compound 27 (5eb) 2-(4-chlorophenyl)-6-fluoro-2,3-dihydroquinazolin-4(1H)-one.




Figure S66 Fig. S28: ¹³C NMR for compound 27 (5eb) 2-(4-chlorophenyl)-6-fluoro-2,3-

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold

dihydroquinazolin-4(1H)-one.




Figure S67 Fig. S28. ^{19}F NMR for compound 27 (5eb) 2-(4-chlorophenyl)-6-fluoro-2,3-dihydroquinazolin-4(1H)-one.





Figure S68 HRMS for compound 27 (5eb) 2-(4-chlorophenyl)-6-fluoro-2,3-dihydroquinazolin-4(1H)-one.



FigureS69

Fig. S29. ¹H NMR for compound 28 (See) 6-fluoro-2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S70 Fig. S29. ¹³C NMR for compound 28 (See) 6-fluoro-2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S71 ^{19}F NMR for compound 28 (5ee) 6-fluoro-2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S72 HRMS for compound 28 (5ee) 6-fluoro-2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S73

Fig. S30: ¹H NMR for compound 29 (5eq) 6-fluoro-2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S74Fig. S30: ¹³C NMR for compound 29 (5eq) 6-fluoro-2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S 75 ^{19}F NMR for compound 29 (5eq) 6-fluoro-2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S 76 HRMS for compound 29 (5eq) 6-fluoro-2-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one.




Figure S77

Fig. S31: ¹H NMR for compound 30 (5fa) 6-methyl-2-phenyl-2,3-dihydroquinazolin-4(1H)-one.




Figure S78 ¹³C NMR for compound 30 (5fa) 6-methyl-2-phenyl-2,3-dihydroquinazolin-4(1H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S79

Fig. S33: ¹H NMR for compound 31 (5fe) 2-(4-methoxyphenyl)-6-methyl-2,3-dihydroquinazolin-4(1H)-one.




Figure S80 ¹³C NMR for compound 31 (5fe) 2-(4-methoxyphenyl)-6-methyl-2,3-dihydroquinazolin-4(1H)-one.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Not Bold




Figure S 81_HRMS for compound 31 (5fe) 2-(4-methoxyphenyl)-6-methyl-2,3-dihydroquinazolin-4(1H)-one.

1. Parua, S.; Das, S.; Sikari, R.; Sinha, S.; Paul, N. D., One-Pot Cascade Synthesis of Quinazolin-4(3H)-ones via Nickel-Catalyzed Dehydrogenative Coupling of *o*-Aminobenzamides with Alcohols. *J Org Chem* **2017**, *82*, (14), 7165-7175, 10.1021/acs.joc.7b00643.
2. Mohammed, S.; Vishwakarma, R. A.; Bharate, S. B., Iodine catalyzed oxidative synthesis of quinazolin-4(3H)-ones and pyrazolo[4,3-d]pyrimidin-7(6H)-ones via amination of sp³ C-H bond. *J Org Chem* **2015**, *80*, (13), 6915-6921, 10.1021/acs.joc.5b00989.
3. Guo, S.; Li, Y.; Tao, L.; Zhang, W.; Fan, X., Rapid assembly of quinazolinone scaffold via copper-catalyzed tandem reaction of 2-bromobenzamides with aldehydes and aqueous ammonia: application to the synthesis of the alkaloid tryptanthrin. *RSC Adv.* **2014**, *4*, (103), 59289-59296, 10.1039/c4ra10799c.
4. Wu, X. F.; He, L.; Neumann, H.; Beller, M., Palladium-catalyzed carbonylative synthesis of quinazolinones from 2-aminobenzamide and aryl bromides. *Chemistry* **2013**, *19*, (38), 12635-12638, 10.1002/chem.201302182.
5. Ghosh, S. K.; Nagarajan, R., Deep Eutectic Solvent Mediated Synthesis of Quinazolinones and Dihydroquinazolinones: Synthesis of Natural Products and Drugs. *RSC Adv.*, **2016**, *6*, 27378-27387, 10.1039/C6RA00855K.
6. Yu, L.; Wang, M.; Li, P.; Wang, L., Fe₃O₄ nanoparticle-supported copper(II): magnetically recoverable and reusable catalyst for the synthesis of quinazolinones and bicyclic pyrimidinones. *Appl Organomet Chem* **2012**, *26*, (11), 576-582, 10.1002/aoc.2902.
7. Huang, H.; Liu, S.; Jean, M.; Simpson, S.; Huang, H.; Merkley, M.; Hayashi, T.; Kong, W.; Rodriguez-Sanchez, I.; Zhang, X.; Yosief, H. O.; Miao, H.; Que, J.; Koble, J. J.; Bradner, J.; Santoso, N. G.; Zhang, W.; Zhu, J., A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. *Front Microbiol* **2017**, *8*, 1035, 10.3389/fmicb.2017.01035.
8. Cao, S. L.; Guo, Y. W.; Wang, X. B.; Zhang, M.; Feng, Y. P.; Jiang, Y. Y.; Wang, Y.; Gao, Q.; Ren, J., Synthesis and Cytotoxicity Screening of Piperazine-1-carbodithioate Derivatives of 2-Substituted Quinazolin-4(3H)-ones. *Archiv Der Pharmazie* **2010**, *342*, (3), 182-189, 10.1002/ardp.200800148.
9. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.; Parker, P.; Workman, P., Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. *Bioorg Med Chem* **2006**, *14*, (20), 6847-6858, 10.1016/j.bmc.2006.06.046.
10. Wu, X.-F.; Oschatz, S.; Block, A.; Spannenberg, A.; Langer, P., Base mediated synthesis of 2-aryl-2,3-dihydroquinazolin-4(1H)-ones from 2-aminobenzonitriles and aromatic aldehydes in water. *Org Biomol Chem* **2014**, *12*, (12), 1865-1870, 10.1039/C3OB42434K.
11. Shiri, L.; Ghorbani-Choghamarani, A.; Kazemi, M., Cu(II) immobilized on Fe₃O₄-diethylenetriamine: A new magnetically recoverable catalyst for the synthesis of 2,3-dihydroquinazolin-4(1H)-ones and oxidative coupling of thiols. *Appl Organomet Chem* **2017**, *31*, (5), e3596, 10.1002/aoc.3596.